Colgate-Palmolive Co. (CL) Falls 3.77% for January 04

Equities Staff |

One of the S&P 500’s big losers for Monday January 04 was Colgate-Palmolive Co. (CL). The company’s stock fell 3.77% to $64.11 on volume of 4.19 million shares.

The stock opened the day at 65.40 and traded between a low of $63.98 and a high of $65.41. The stock finished the day down $2.51 per share. Colgate-Palmolive Co. has an average daily volume of 3.61 million and a total float of 896.92 million shares. The 50-day SMA for Colgate-Palmolive Co. is $66.72 and its 200-day SMA is $66.19. The high for the stock over the last 52 weeks is $71.56 and the low is $50.84.

Colgate-Palmolive Co is a consumer products company. The Company provides services such as oral care, personal care, home care and pet nutrition.

Colgate-Palmolive Co. is centered in New York, NY, and has 37,700 employees. Today’s trading day leaves the company with a market cap of $57.5 billionwith a P/E Ratio of 24.7. The company has a P/S ratio of 4.92, P/B ratio of 228.96, and a 72.5.

For a complete fundamental analysis analysis of Colgate-Palmolive Co., check out’s Stock Valuation Analysis report for CL. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

PixarBio Corp

PixarBio Corp is a specialty pharmaceutical/biotechnology company focused on pre-clinical and commercial development of novel neurological drug delivery systems for post-operative pain.

Private Markets


Blockchain currencies (e.g. Bitcoin) provide a new disruptive way to transfer value between parties over the internet as opposed to going through banks. GoCoin provides online merchants with a suite…


Our mission is to be the best place for people who care about music to create and discover thoughtfully curated playlists. In essence, 8tracks is a platform for online mixtapes.